Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cyclophosphamide so-so verdict in progressive MS
Impact of Depression, Fatigue and Disability on Quality of Life in Chinese Patients with Multiple Sclerosis.
Clinical analysis of the etiology of optic neuritis in patients at different ages in china.
The genetic and environmental bases of complex human-disease: extending the utility of twin-studies.
Cortical Perfusion Alteration in Normal-Appearing Gray Matter Is Most Sensitive to Disease Progression in Relapsing-Remitting Multiple Sclerosis.
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis.
Riluzole increases glutamate uptake by cultured C6 astroglial cells.
17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.
Secukinumab shines in small MS trial
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis.
Multiple sclerosis and stress.
[Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features.]
Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
Complex molecular and functional outcomes of single versus sequential cytokine stimulation of rat microglia.
Transcriptomic meta-analysis of multiple sclerosis and its experimental models.
MRI characteristics of familial and sporadic multiple sclerosis patients.
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.
White matter volume is decreased in the brain of patients with neuromyelitis optica.

Pages